A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease



Status:Active, not recruiting
Conditions:Alzheimer Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:50 - 90
Updated:3/8/2019
Start Date:February 26, 2015
End Date:March 26, 2019

Use our guide to learn which trials are right for you!

A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease

This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the
safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72
participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination
[MMSE] 18 to 28 points, inclusive). An optional open-label extension (OLE) will be offered
after the completion of initial double-blind stage.


Inclusion Criteria:

- Body weight greater than or equal (>/=) 45 kilograms (kg) and less than or equal ( 120 kg

- Ages 50-90 years, inclusive

- Availability of a person ("caregiver") who, in the investigator's judgment, has
frequent and sufficient contact with the participant and is able to provide accurate
information regarding the participant's cognitive and functional abilities, agrees to
provide information at clinic visits, which require partner input for scale
completion, and signs the necessary consent form

- Willingness and ability to complete all aspects of the study; the participant should
be capable of completing assessments either alone or with the help of the caregiver

- Adequate visual and auditory acuity, in the investigator's judgment, sufficient to
perform the neuropsychological testing

- Clinical diagnosis of probable mild to moderate AD based on the national institute on
neurological and communication disease and stroke/Alzheimer's disease and related
disorders association (NINCDS/ADRDA) criteria or probable major neurocognitive
disorder due to AD of mild to moderate severity based on diagnostic and statistical
manual of mental disorders, version 5 (DSM-5) criteria

- Screening MMSE score of 18-28 points, inclusive

- Screening clinical dementia rating global score (CDR-GS) of 0.5 or 1.0

- Screening geriatric depression (GDS)-15 score less than (<) 6

- Positive florbetapir amyloid positron emission tomography (PET) scan by qualitative
read conducted by the core/central PET laboratory

- Women must be postmenopausal or surgically sterile

- Men with female partners of childbearing potential agree to remain abstinent or use
adequate methods of contraception as defined by protocol during the treatment period
and for at least 8 weeks after the last dose of study drug and agreement to refrain
from donating sperm during this same period

Exclusion Criteria:

- History or presence of clinically evident vascular disease potentially affecting the
brain that, in the opinion of the investigator, has the potential to affect cognitive
function

- History or presence of stroke within the previous 2 years or documented history of
transient ischemic attack within the previous 12 months

- History of severe, clinically significant central nervous system trauma

- History or presence of intracranial tumor that is clinically relevant in the opinion
of the investigator

- Presence of infections that affect brain function or history of infections that
resulted in neurologic sequelae

- History or presence of systemic autoimmune disorders potentially causing progressive
neurologic disease with associated cognitive deficits

- History or presence of a neurologic disease other than AD that may affect cognition

- Presence of superficial siderosis, more than four cerebral microhemorrhages, or
evidence of a prior cerebral macrohemorrhage

- Inability to tolerate magnetic resonance imaging (MRI) procedures or contraindication
to MRI

- History or presence of atrial fibrillation except if only one episode that resolved
more than 1 year ago and for which treatment is no longer indicated or that in the
investigator's judgment poses no risk for future stroke

- Within the previous 2 years, unstable or clinically significant cardiovascular disease

- Uncontrolled hypertension

- Chronic kidney disease of Stage >/= 4, according to the national kidney foundation
kidney disease outcomes quality initiative (NKF KDOQI) guidelines for chronic kidney
disease

- Impaired hepatic function

- Clinically significantly abnormal screening blood or urine that remain abnormal on
retest

- History of malignancies within 5 years prior to screening, except for appropriately
treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I
uterine cancer; cancer that is considered likely to be cured, is not being actively
treated with anti-cancer therapy or radiotherapy and not likely to require treatment
in the ensuing 5 years as well as cancers that are considered to have low probability
of recurrence are allowed

- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric, human, or humanized antibodies or fusion proteins

- Severe or unstable medical condition that, in the opinion of the investigator or
sponsor, could be expected to progress, recur, or change to such an extent that it
could put the patient at special risk, bias the assessment of the clinical or mental
status of the patient to a significant degree, interfere with the patient's ability to
complete the study assessments, or would require the equivalent of institutional or
hospital care

- Any previous treatment with medications used to treat Parkinsonian symptoms or any
other neurodegenerative disorder within 1 year before screening even if the patient is
taking the medicine for a non-neurodegenerative disorder such as restless leg disorder

- Typical anti-psychotic or neuroleptic medication within 6 months before screening
except as brief treatment for a non-psychiatric indication

- Antihemostasis medication within 2 weeks before screening

- Sedative, hypnotic, or benzodiazepine medication within 3 months before screening
except intermittent use of the following for sleep or anxiety: alprazolam, lorazepam,
oxazepam, temazepam, diazepam, or a short-acting benzodiazepine-like medication
We found this trial at
13
sites
Phoenix, Arizona 85054
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
316 Calhoun St
Charleston, South Carolina 29401
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Delray Beach, Florida 33445
?
mi
from
Delray Beach, FL
Click here to add this to my saved trials
East Providence, Rhode Island 02914
?
mi
from
East Providence, RI
Click here to add this to my saved trials
Hattiesburg, Mississippi 39401
?
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
355 West 16th Street
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Miami, Florida 33137
?
mi
from
Miami, FL
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Saint Louis, Missouri 63132
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
The Villages, Florida 32162
?
mi
from
The Villages, FL
Click here to add this to my saved trials